What Are Analysts Report About Endo International plc (ENDP)
William Blair has a “Market Perform” rating on the stock. On a one to five ratings scale where 1 refers to a Strong Buy, 2 directs a Buy, 3 a Hold, 4 indicates a Sell and 5 a Strong Sell.
Endo International plc – Ordinary Shares (NASDAQ:ENDP) shares traded during its most recent trading session in the range of $13.37 – $13.86. Oppenheimer Holdings Inc. reissued a “hold” rating on shares of Endo International plc – in a report on Wednesday, March 1st.
Endo International plc (ENDP) surprised the stock market in its last reported earnings when it earned $1.23 a piece versus the consensus-estimated $1.1. The Company has 52-week high of $24.93 and 52-week low of $9.70. Endo International plc – has an average rating of “Hold” and an average price target of $19.74. The firm has a 50 day moving average price of $11.35 and a 200 day moving average price of $13.48. Market capitalization (market cap) is the total dollar market value of all of a company’s outstanding shares.
Another critical number in evaluating a stock is P/E or the price to earnings ratio.
Currently, EPS of Endo International plc (ENDP) is 1.23 while the analysts predicted the EPS of the stock to be 1.1 suggesting the company fell short of the analysts’ expectations. The business had revenue of $1.04 billion during the quarter, compared to analyst estimates of $1.02 billion.
The company’s net profit margin stands at -82.90% whereas its return on equity (ROE) is -78.80%.
The company’s expected revenue in the current quarter to be 841 Million, seeing a projected current quarter growth of -12.8%, and per annum growth estimates over the next 5 year period of around -3.4%. During the same quarter in the prior year, the company posted ($0.11) EPS.
While arriving at a price target, analysts and investors alike use various metrics to determine where the stock might be directed. Proficio Capital Partners LLC boosted its position in shares of Target by 2,193.7% in the first quarter. Macquarie Group Ltd. now owns 6,500 shares of the company’s stock valued at $107,000 after buying an additional 3,700 shares in the last quarter. Acrospire Investment Management LLC increased its stake in Endo International plc – by 139.3% in the third quarter. Taking a look into the performance of ENDP stock, investor will come to know that the weekly performance for this stock is valued at 24.06%, resulting in a performance for the month at 25.21%.
While looking at the Stock’s Performance, Endo International plc now shows a Weekly Performance of 18.83%, where Monthly Performance is 26.12%, Quarterly performance is 12.52%, 6 Months performance is -16.65% and yearly performance percentage is 0.89%. Point View Wealth Management Inc. now owns 11,431 shares of the company’s stock worth $128,000 after buying an additional 1,254 shares in the last quarter. Perceptive Advisors LLC acquired a new stake in shares of Endo International plc – during the fourth quarter worth approximately $213,000. Point72 Asset Management L.P. acquired a new position in shares of Time during the first quarter worth about $29,239,000. They have a dividend yield of 0.00% and a 5 year dividend growth rate of 0.00%.
In other news, Director Nancy J. Hutson sold 5,325 shares of the company’s stock in a transaction dated Thursday, March 9th. If the share price is now hovering near the 52 week low and the value is achieved in the current past then it can suggest that the price of the shares is likely to go up. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Its International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas, including attention deficit hyperactivity disorder, pain, womenÂ’s health, and oncology; generic, branded generic, and over-the-counter products in the areas of dermatology and anti-infectives; and healthcare services, products, and solutions to hospitals, pharmacies, and practitioners, as well as for government healthcare programs.